COmpliance and Efficacy in Mono and Combination Tablet Study ATacand/Atacand Plus
Completed
- Conditions
- Hypertension
- Registration Number
- NCT00526279
- Lead Sponsor
- AstraZeneca
- Brief Summary
To evaluate compliance and patients' satisfaction in mono and combination treatment of Candesartan cilexetil (Atacand)/ Candesartan cilexetil 16mg, hydrochlorothiazide 12.5mg (Atacand plus) in hypertension.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 9000
Inclusion Criteria
- Patients who have consented to participation/data release in this study
- Patients diagnosed with hypertension and prescribed with atacand/atacand plus by the physician based on clinical decision
Exclusion Criteria
- Secondary hypertension requiring therapy other than antihypertensive medication
- Patients not prescribed with atacand/atacand plus based on safety reasons or any other reason as determined by the physician
- Women in pregnancy or lactation
- Patients enrolled in any other studies
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Research Site
🇰🇷Seoul, Songpa-gu, Korea, Republic of